Why summer is a documented quality problem in this trade
The route did not close because of a rule about peptides.
Archive — July 2025
Page 5 of 5 of this archive, newest first.
SURMOUNT-4 extension data: what happens after the trial stops
A design note rather than a result: what the comparator was, and what that permits you to conclude.
Holograms, QR codes and other things that are not verification
Reported from the analysis, not from a warning notice.
What a diode array adds, and why the certificate never shows it
A diode-array detector records the whole spectrum at every time point and can confirm that a peak is spectrally homogeneous. Almost nobody prints that information.
Which results should be repeated before they are investigated
What the pivotal programmes measured and how often, which is a more defensible template than most published monitoring schedules.
Electrospray, MALDI, and the choice that shapes every spectrum after it
The two ionisation techniques in general use produce different charge distributions, different adducts and different failure modes. Certificates almost never say which was…
The slide that was not in the abstract
Reported from the sessions, and from the two hours afterwards.
Switzerland pharmacy body issues counselling standards for liraglutide initiation
The evidence base is thin and the document says so, which is to its credit.
Zhuhai export categories for peptide intermediates were quietly renamed
Follow the resin, not the catalogue.
Independent analysis puts a FGP retatrutide lot at 97.1%, against 95.4% on the certificate
The result is unremarkable. What the report omits is not.